Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paxil CR For PMDD: FDA Decision Expected In “Coming Months,” GSK Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline expects to hear from FDA “in the coming months” on a pending premenstrual dysphoric disorder indication for its antidepressant Paxil CR.
Advertisement

Related Content

GSK Paxil CR PMDD approval
Paxil CR Vs. IR: GI Tolerability Claim Would Require Comparative Trials - FDA
Paxil CR Vs. IR: GI Tolerability Claim Would Require Comparative Trials - FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS002304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel